House committee report shines light on pharma’s pricing, business practices
![](/sites/default/files/styles/900x400/public/2018-02/pharmacy_pills.jpg?itok=KcMX5HRi)
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released Thursday by the House Committee on Oversight and Reform.
For the same time period, the report notes that the companies’ top executives earned more as they raised drug prices, with salaries growing by 14% and compensation totaling $3.2 billion. In addition, findings show research and development budgets were spent “on finding ways to suppress generic and biosimilar competition while continuing to raise prices, rather than on innovative research.”
Related News Articles
Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Headline
Blog, infographic highlight how increasing drug prices and shortages are jeopardizing access to care
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…